Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 20/20 | 0.68 |
| ▸ | KIT | P10721 | 2/20 | 0.62 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16345690 | 0.81 | GAK (0.78) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL16347758 | 0.81 | GAK (1.00) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL16347773 | 0.79 | GAK (1.00) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL16345746 | 0.79 | GAK (0.81) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL16346280 | 0.78 | GAK (1.00) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL16347538 | 0.78 | GAK (1.00) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL17721345 | 0.77 | GAK (0.78) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL16346186 | 0.77 | GAK (1.00) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL16347598 | 0.77 | GAK (1.00) | GAKKITCSF1RPDGFRBPDGFRA | |
| SCHEMBL16346579 | 0.76 | GAK (0.80) | GAKKITCSF1RPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152271-A1 | GAK MODULATORS AS ANTIVIRALS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-06-01 | — | — | US | claimed |
| US-9518066-B2 | GAK modulators | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-12-13 | — | — | US | claimed |
| EP-3016958-A1 | NOVEL GAK MODULATORS | Katholieke Universiteit Leuven (BE) | 2016-05-11 | — | — | EP | claimed |
| US-20160122364-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-05-05 | — | — | US | claimed |
| WO-2016012536-A1 | GAK MODULATORS AS ANTIVIRALS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-01-28 | — | — | WO | claimed |
| WO-2015001076-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-01-08 | — | — | WO | claimed |
| US-9822127-B2 | GAK modulators as antivirals | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822127-B2 | GAK modulators as antivirals | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822127-B2 | GAK modulators as antivirals | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170152271-A1 | GAK MODULATORS AS ANTIVIRALS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152271-A1 | GAK MODULATORS AS ANTIVIRALS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152271-A1 | GAK MODULATORS AS ANTIVIRALS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-06-01 | — | — | US | disclosed |
| US-9518066-B2 | GAK modulators | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-12-13 | — | — | US | disclosed |
| US-9518066-B2 | GAK modulators | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-12-13 | — | — | US | disclosed |
| EP-3016958-A1 | NOVEL GAK MODULATORS | Katholieke Universiteit Leuven (BE) | 2016-05-11 | — | — | EP | disclosed |
| US-20160122364-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122364-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122364-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-05-05 | — | — | US | disclosed |
| WO-2016012536-A1 | GAK MODULATORS AS ANTIVIRALS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015001076-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122364-A1 | NOVEL GAK MODULATORS | GAK, CAMKK2, GRK3 | GAK 1/4885KIT 1031/4885CSF1R 2127/4885 |
| US-20170152271-A1 | GAK MODULATORS AS ANTIVIRALS | GAK, IRF3, EIF2AK2 | GAK 1/4885KIT 2008/4885CSF1R 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.